Celularity Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
123
- Stock Symbol
-
CELU
- Investments
-
5
- Share Price
-
$2.48
- (As of Tuesday Closing)
Celularity General Information
Description
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
Contact Information
Website
www.celularity.comCorporate Office
- 170 Park Avenue
- Florham Park, NJ 07039
- United States
Corporate Office
- 170 Park Avenue
- Florham Park, NJ 07039
- United States
Celularity Timeline
Celularity Stock Performance
As of 15-Jul-2025, Celularity’s stock price is $2.48. Its current market cap is $59.4M with 23.9M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.48 | $2.24 | $1.00 - $5.22 | $59.4M | 23.9M | 198K | -$2.64 |
Celularity Financials Summary
As of 31-Dec-2024, Celularity has a trailing 12-month revenue of $54.2M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 115,695 | 115,695 | 106,102 | 211,590 |
| Revenue | 54,220 | 54,220 | 22,771 | 17,975 |
| EBITDA | (44,037) | (44,037) | (184,266) | 23,276 |
| Net Income | (57,892) | (57,892) | (196,295) | 14,192 |
| Total Assets | 132,682 | 132,682 | 143,889 | 401,066 |
| Total Debt | 68,836 | 68,836 | 65,417 | 65,588 |
Celularity Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Celularity Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Celularity Comparisons
Industry
Financing
Details
Celularity Competitors (84)
One of Celularity’s 84 competitors is Fate Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| ImmunityBio | Formerly VC-backed | San Diego, CA | ||||
| Century Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| Senti Bio | Formerly VC-backed | South San Francisco, CA |
Celularity Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Celularity Patents
Celularity Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023206330-A1 | Cleavage resistant cd16 constructs and uses thereof | Pending | 11-Jan-2022 | ||
| EP-4463474-A1 | Cleavage resistant cd16 constructs and uses thereof | Pending | 11-Jan-2022 | ||
| AU-2022257116-A1 | Multi-layer amniotic tissue grafts and uses thereof | Pending | 13-Apr-2021 | ||
| CA-3216040-A1 | Multi-layer amniotic tissue grafts and uses thereof | Pending | 13-Apr-2021 | ||
| US-20240245830-A1 | Multi-layer amniotic tissue grafts and uses thereof | Pending | 13-Apr-2021 | A61L27/3633 |
Celularity Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Celularity Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Celularity Investments & Acquisitions (5)
Celularity’s most recent deal was a Corporate Asset Purchase with Sequence LifeScience (Rebound Matrix) for . The deal was made on 09-Oct-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sequence LifeScience (Rebound Matrix) | 09-Oct-2024 | Corporate Asset Purchase | Buildings and Property | ||
| GX Acquisition | 16-Jul-2021 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| Caricord | 31-Aug-2018 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| Alliqua BioMedical (Biologic Wound Care Assets) | 07-May-2018 | Corporate Asset Purchase | Buildings and Property | ||
| HLI Cellular Therpaeutics | 31-May-2017 | Merger/Acquisition | Biotechnology |
Celularity ESG
Risk Overview
Risk Rating
Updated June, 21, 2023
23.25 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,842
Rank
Percentile
Commercial Services
Industry
of 462
Rank
Percentile
Business Support Services
Subindustry
of 176
Rank
Percentile
Celularity FAQs
-
When was Celularity founded?
Celularity was founded in 1998.
-
Where is Celularity headquartered?
Celularity is headquartered in Florham Park, NJ.
-
What is the size of Celularity?
Celularity has 123 total employees.
-
What industry is Celularity in?
Celularity’s primary industry is Drug Discovery.
-
Is Celularity a private or public company?
Celularity is a Public company.
-
What is Celularity’s stock symbol?
The ticker symbol for Celularity is CELU.
-
What is the current stock price of Celularity?
As of 15-Jul-2025 the stock price of Celularity is $2.48.
-
What is the current market cap of Celularity?
The current market capitalization of Celularity is $59.4M.
-
What is Celularity’s current revenue?
The trailing twelve month revenue for Celularity is $54.2M.
-
Who are Celularity’s competitors?
Fate Therapeutics, Arvinas, ImmunityBio, Century Therapeutics, and Senti Bio are some of the 84 competitors of Celularity.
-
What is Celularity’s annual earnings per share (EPS)?
Celularity’s EPS for 12 months was -$2.64.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
